Want to see KR:019170 full AI Analyst Report?
019170 Stock Chart & Stats
₩8460.00
₩110.00(1.32%)
―
--
Day’s Range― - ―
52-Week Range₩6,310.00 - ₩15,750.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)372.06K
Market Cap
₩435.39B
Enterprise Value₩433.99B
Total Cash (Recent Filing)₩72.30B
Total Debt (Recent Filing)₩53.28B
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-9.55
Shares Outstanding52,418,520
10 Day Avg. Volume350,855
30 Day Avg. Volume372,065
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)2.87
Price to Sales (P/S)3.30
P/FCF Ratio56.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate leverage gives Shinpoong financial flexibility to fund operations and selected development efforts without excessive balance-sheet strain. A sizable equity base and stable-to-growing assets also provide resilience as the company works through uneven profitability and cash-generation performance.
Broad Pharmaceutical PlatformShinpoong’s integrated prescription-drug model spans research, development, manufacturing, and marketing, while its products cover multiple therapeutic areas. This platform can support recurring product activity and reduce reliance on a single treatment category as the business develops domestic and overseas opportunities.
Advanced Stroke Drug DevelopmentThe revised large-scale Phase 3 program for SP-8203 represents a meaningful late-stage development opportunity in acute ischemic stroke. If the trial confirms benefit alongside thrombolytic therapy, the candidate could strengthen Shinpoong’s future product portfolio and competitive position, although development risk remains.
Bears Say
Renewed TTM LossesThe return to a slight TTM loss after 2025 profitability shows that Shinpoong’s earnings recovery is not yet durable. Operating margin compression leaves less protection against revenue or cost pressure, making future investment capacity and shareholder returns more dependent on renewed execution.
Weakening Free Cash Flow MomentumPositive operating and free cash flow are an improvement over earlier loss years, but the sharp TTM free-cash-flow decline questions the consistency of internal cash generation. Weak conversion relative to the reported earnings base could constrain sustained funding for development, operations, and other strategic priorities.
Inconsistent ProfitabilityVolatile revenue performance and inconsistent profitability indicate that Shinpoong has not yet established a stable earnings trajectory. Even with a solid gross margin and a 2025 profit, uneven results and negative returns in multiple periods suggest the asset base is not consistently translating into durable shareholder value.
Shinpoong Pharmaceutical Co., Ltd. News
019170 FAQ
What was Shinpoong Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Shinpoong Pharmaceutical Co., Ltd. lowest stock price was ₩6310.00 and its highest was ₩15750.00 in the past 12 months.
What is Shinpoong Pharmaceutical Co., Ltd.’s market cap?
Shinpoong Pharmaceutical Co., Ltd.’s market cap is ₩435.39B.
When is Shinpoong Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Shinpoong Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 20 days.
How were Shinpoong Pharmaceutical Co., Ltd.’s earnings last quarter?
Shinpoong Pharmaceutical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -₩149.229 earnings per share for the quarter.
Is Shinpoong Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Shinpoong Pharmaceutical Co., Ltd.’s price is currently Undervalued.
Does Shinpoong Pharmaceutical Co., Ltd. pay dividends?
Shinpoong Pharmaceutical Co., Ltd. pays a Notavailable dividend of ₩100 which represents an annual dividend yield of 0.08%. See more information on Shinpoong Pharmaceutical Co., Ltd. dividends here
What is Shinpoong Pharmaceutical Co., Ltd.’s EPS estimate?
Shinpoong Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shinpoong Pharmaceutical Co., Ltd. have?
Shinpoong Pharmaceutical Co., Ltd. has 52,418,520 shares outstanding.
What happened to Shinpoong Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Shinpoong Pharmaceutical Co., Ltd. reported an EPS of -₩149.229 in its last earnings report. Following the earnings report the stock price went up 0.457%.
Which hedge fund is a major shareholder of Shinpoong Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:019170
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shinpoong Pharmaceutical Co., Ltd.
Shinpoong Pharmaceutical Co., Ltd. is a South Korean company that manufactures and distributes a broad spectrum of pharmaceutical products. Its portfolio includes both cephalosporin and penicillin antibiotics, alongside other finished medications. The company also produces active pharmaceutical ingredients (APIs) and offers specialized drugs such as Pyramax, an anti-malarial treatment, as well as therapies for hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and surgical adhesion prevention. Furthermore, they market various over-the-counter (OTC) products. Founded in 1962 and headquartered in Seoul, South Korea, Shinpoong Pharmaceutical extends its market reach internationally, exporting its goods to roughly 50 countries.
Technical Analysis
JW Pharmaceutical Corporation
―
Bukwang Pharmaceutical Co., Ltd.
―
Kwang Dong Pharmaceutical Co., Ltd.
―
Dong-A ST Co., Ltd.
―
Ildong Pharmaceutical Co., Ltd.
―